Nkarta Inc
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Nkarta Inc
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Nkarta Inc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Nkarta Inc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Nkarta Inc is NKTX:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Nkarta Inc has its primary listing on NASDAQ. You can trade Nkarta Inc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Nkarta Inc is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Nkarta Inc as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Nkarta Inc.